Clinical utility of 30-min plasma glucose for prediction of type 2 diabetes among people with prediabetes: Ancillary analysis of the diabetes community lifestyle improvement program.
30-min-plasma glucose
Diabetes prediction
Net reclassification improvement
OGTT
Prediabetes
Predictive utility
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
17
09
2019
revised:
06
02
2020
accepted:
10
02
2020
pubmed:
15
2
2020
medline:
27
6
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
To examine the clinical utility of 30-min plasma glucose (30-min-PG) measurement during an oral glucose tolerance (OGTT) in predicting type 2 diabetes (T2DM). Data from a 3-year, randomized, controlled, primary prevention trial among 548 Asian Indians with prediabetes were analyzed. Participants underwent OGTT with PG measurements at fasting, 30-min, and 2-h at baseline and annually until the end of the study. Multivariable Cox regression models were constructed to calculate the risk of developing diabetes based on 30-min-PG levels. Improvement in prediction performance gained by adding an elevated level of 30-min-PG over prediabetic categories was calculated using the area-under-curve (AUC), net-reclassification (NRI), and integrated discrimination improvement (IDI) statistics. At the end of follow-up, 30.4% of individuals had been diagnosed with T2DM by ADA criteria. Based on the maximally selected log-rank statistics, the optimal 30-min-PG cut point for predicting incident T2DM was >182 mg/dl. Multivariable-adjusted Cox regression models showed an independent association between elevated 30-min-PG (>182 mg/dl) and incident diabetes (hazard ratio (95% CI): 1.85 [1.32, 2.59]; D In prediabetic individuals, baseline 30-min-PG independently predicted T2DM and significantly improved reclassification and discrimination. Therefore, 30-min-PG should be considered as part of the routine testing in addition to FPG and 2-h-PG for better risk stratification.
Identifiants
pubmed: 32057962
pii: S0168-8227(19)31339-7
doi: 10.1016/j.diabres.2020.108075
pmc: PMC7106975
mid: NIHMS1574613
pii:
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
108075Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268200900026C
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111024
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125442
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declared that there is no conflict of interest.
Références
Diabetes Care. 2018 Jan;41(1):171-177
pubmed: 29138275
Diabetes Metab Res Rev. 2016 Oct;32(7):762-767
pubmed: 26991329
Diabetes. 2002 Feb;51 Suppl 1:S109-16
pubmed: 11815468
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Diabetes Care. 2016 Oct;39(10):1760-7
pubmed: 27504014
Eur J Endocrinol. 2006 Jul;155(1):191-7
pubmed: 16793967
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1131-1140
pubmed: 30445509
Diabet Med. 2002 Sep;19(9):708-23
pubmed: 12207806
Diabetes Care. 2008 Aug;31(8):1650-5
pubmed: 18487478
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Diabetes Metab Res Rev. 2010 May;26(4):280-6
pubmed: 20503260
Diabetologia. 2015 Jan;58(1):87-97
pubmed: 25292440
Am J Physiol. 1989 Aug;257(2 Pt 1):E241-6
pubmed: 2669517
Prim Care Diabetes. 2012 Apr;6(1):3-9
pubmed: 21616737
Diabetes Care. 2009 Feb;32(2):281-6
pubmed: 19017778
Lancet Diabetes Endocrinol. 2018 Oct;6(10):781-789
pubmed: 30224284
Diabetologia. 2017 Jul;60(7):1252-1260
pubmed: 28409212
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Diabetes. 2014 Jan;63(1):53-5
pubmed: 24357697
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Diabetes Res Clin Pract. 2018 Dec;146:18-33
pubmed: 30273707